Pathogenesis of Emerging and Re-emerging Diseases: Ebola Virus Disease
Abstract
<h2>Cover Page</h2> <p><strong>Pathogenesis of Emerging and Re-emerging Diseases: Ebola Virus Disease</strong></p> <p>Student Name</p> <p>Institutional Affiliation</p> <p>Course</p> <p>Instructor's Name</p> <p>Date</p> <h2>Overview of Ebola Virus Disease</h2> <p>Ebola Virus Disease (EVD) is a severe emerging zoonotic disease caused by the Ebola virus, a member of the Filoviridae family. First identified during simultaneous outbreaks in Sudan and the Democratic Republic of Congo in 1976, Ebola has remained a major global public health concern because of its high mortality rate and potential for rapid transmission. Fruit bats are considered the primary natural reservoir, while increasing urbanization, international travel, weak healthcare systems, and political instability have contributed to larger and more widespread outbreaks.</p> <h2>Microbiological Characteristics and Disease Pathogenesis</h2> <p>Ebola virus is a negative-sense single-stranded RNA virus that infects multiple cell types, including macrophages, dendritic cells, and endothelial cells. Infection triggers widespread immune dysregulation, excessive inflammatory responses, vascular damage, coagulation abnormalities, and multi-organ dysfunction. Clinical illness typically begins with fever, fatigue, headache, and muscle pain before progressing to gastrointestinal symptoms, hemorrhage, and severe systemic complications. Among the known virus species, the Zaire strain has demonstrated the highest fatality rate.</p> <h2>Global Distribution and Populations at Risk</h2> <p>Ebola outbreaks primarily occur in Central and West Africa, particularly within the Democratic Republic of Congo, Guinea, Liberia, Sierra Leone, and neighboring countries. Healthcare workers, caregivers, individuals involved in traditional burial practices, and populations with limited access to healthcare services face the greatest risk of infection. Pregnant women and individuals living in resource-limited settings are especially vulnerable to severe disease outcomes.</p> <h2>Transmission, Diagnosis, and Clinical Management</h2> <p>The incubation period ranges from two to twenty-one days, with infected individuals becoming contagious after symptoms appear. Transmission occurs through direct contact with infected body fluids or contaminated materials. Diagnosis relies on clinical assessment, exposure history, polymerase chain reaction (PCR) testing, antigen detection assays, and rapid diagnostic tests. Although no universally approved antiviral cure exists, supportive care—including fluid replacement, electrolyte management, oxygen therapy, symptom control, and strict infection prevention measures—remains the cornerstone of treatment.</p> <h2>Laboratory Testing and Public Health Surveillance</h2> <p>Laboratory assessment of immunity commonly utilizes enzyme-linked immunosorbent assay (ELISA) to detect Ebola-specific antibodies, while rapid diagnostic tests provide timely identification in resource-limited environments. Confirmed cases should be reported promptly to national health authorities, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) to facilitate surveillance, outbreak response, and international disease control efforts.</p> <h2>Strategies for Prevention and Disease Control</h2> <p>Reducing Ebola transmission requires comprehensive public health interventions, including strengthened surveillance systems, early outbreak detection, rapid isolation of suspected cases, effective infection prevention and control practices, community education, vaccination programs where available, healthcare capacity strengthening, and continued research into vaccines and therapeutics. International collaboration remains essential for limiting cross-border transmission and improving global preparedness for future outbreaks.</p> <h2>Conclusion</h2> <p>Ebola Virus Disease remains one of the world's most serious emerging infectious diseases because of its high mortality, rapid progression, and epidemic potential. Effective disease control depends on timely diagnosis, supportive clinical management, strong public health infrastructure, continuous surveillance, and coordinated international response. Continued investment in research, vaccination, and healthcare preparedness is essential to reducing the global burden of Ebola.</p> <h2>References</h2> <p>References should remain exactly as presented in the original document.</p>